or Try an Advanced Search...

    Protein Kinase Inhibitor Stocks List

    Symbol Grade Name % Change
    ACLX D Arcellx, Inc. -0.47
    ALLR F Allarity Therapeutics, Inc. -18.68
    AVBP F ArriVent BioPharma, Inc. 0.06
    BBIO F BridgeBio Pharma, Inc. -1.07
    BPMC B Blueprint Medicines Corporation 2.16
    COGT C Cogent Biosciences, Inc. 2.51
    CRIS B Curis, Inc. 0.19
    DAWN B Day One Biopharmaceuticals, Inc. 2.89
    DCPH A Deciphera Pharmaceuticals, Inc. 0.04
    ELVN B Enliven Therapeutics, Inc. 7.77
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Biopharmaceutical Tyrosine Kinase Tyrosine Kinase Receptors Drugs Enzymes Gastrointestinal Gastrointestinal Stromal Tumor Mastocytosis Solid Tumors Systemic Mastocytosis Antineoplastic Drugs Biotechnology Cancer Treatment Clinical Development Clinical Medicine Fibroblast Growth Factor Receptor Gastrointestinal Stromal Tumors Lung Cancer Medicine

    Related ETFs - A few ETFs which own one or more of the above listed Protein Kinase Inhibitor stocks.

    Symbol Grade Name Weight
    BBP C BioShares Biotechnology Products Fund 9.11
    IDNA C iShares Genomics Immunology and Healthcare ETF 8.74
    CNCR D Loncar Cancer Immunotherapy ETF 6.83
    PBE C PowerShares Dynamic Biotech & Genome 6.16
    LABD D Direxion Daily S&P Biotech Bear 3X Shares 5.24
    View all Protein Kinase Inhibitor ETFs...
    Compare ETFs
    Compare BBP to IDNA Compare CNCR to LABD Compare IDNA to LABD

        Protein Kinase Inhibitor Stocks Recent News

        Date Stock Title
        May 8 CRIS Curis, Inc. (CRIS) Q1 2024 Earnings Call Transcript
        May 7 COGT Cogent Biosciences EPS of -$0.62 misses by $0.11
        May 7 ALLR All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy
        May 7 ALLR Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
        May 7 CRIS Curis GAAP EPS of -$2.05, revenue of $2.1M
        May 7 COGT Cogent Biosciences Reports First Quarter 2024 Financial Results
        May 7 CRIS Curis Provides First Quarter 2024 Business Update
        May 7 BPMC Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
        May 6 DAWN Day One Biopharmaceuticals GAAP EPS of -$0.72 misses by $0.06
        May 6 DAWN Day One Reports First Quarter 2024 Financial Results and Corporate Progress
        May 6 CRIS Curis Q1 2024 Earnings Preview
        May 6 BPMC 5 Biotech Stocks Worth Adding to Your Portfolio in 2024
        May 6 ALLR Allarity exceeds Nasdaq's minimum equity requirement
        May 6 ALLR Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
        May 5 DCPH Wall Street Breakfast: The Week Ahead
        May 4 BBIO What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
        May 4 BPMC Blueprint Medicines: Rampant Growth Mostly Priced In
        May 4 DAWN Insider Sale at Day One Biopharmaceuticals Inc (DAWN)
        May 3 BPMC Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript
        May 3 BPMC Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Biopharmaceutical Tyrosine Kinase Drugs Solid Tumors Tyrosine Kinase Receptors Treatment Of Cancer Antineoplastic Drugs Biotechnology Blastoma Breast Cancer Cancer Treatment Clinical Development Fibroblast Growth Factor Receptor Gastrointestinal Gastrointestinal Stromal Tumor Glioblastoma Glioblastoma Multiforme Lung Cancer Lymphoma
        Protein Kinase Inhibitor

        Protein kinase inhibitors are drugs that block the activity of one or more protein kinases. Protein kinases are enzymes that add phosphate groups to proteins, which can alter their activity and function. Protein kinase inhibitors are used to treat a variety of diseases, including cancer, inflammation, and autoimmune disorders.

        Browse All Tags